Cover Image
市場調查報告書

酪胺酸蛋白質激梅JAK1:開發中產品分析

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 367826
出版日期 內容資訊 英文 155 Pages
訂單完成後即時交付
價格
Back to Top
酪胺酸蛋白質激梅JAK1:開發中產品分析 Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2018
出版日期: 2018年05月22日 內容資訊: 英文 155 Pages
簡介

本報告提供以酪胺酸蛋白質激梅JAK1為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

酪胺酸蛋白質激梅JAK1 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • AbbVie Inc
  • Aclaris Therapeutics Inc
  • Advinus Therapeutics Ltd
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Chipscreen Biosciences Ltd
  • CJ HealthCare Corp
  • Eli Lilly and Company
  • Galapagos NV
  • Incyte Corp
  • 日本煙草產業
  • Jiangsu Hengrui Medicine Co Ltd
  • 日產化學工業
  • Pfizer Inc
  • Portola Pharmaceuticals Inc
  • Sareum Holdings Plc
  • Theravance Biopharma Inc
  • Vectura Group Plc

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1457TDB

Summary

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 28 molecules. The latest report Tyrosine Protein Kinase JAK1 - Pipeline Review, H1 2018, outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body.

The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 5, 4, 9 and 2 respectively. Report covers products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Hematological Disorders, Ophthalmology and Respiratory which include indications Rheumatoid Arthritis, Atopic Dermatitis, Alopecia, Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Diffuse Large B-Cell Lymphoma, Psoriasis, Psoriatic Arthritis, Vitiligo, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Ankylosing Spondylitis (Bekhterev's Disease), B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Giant Cell Arteritis, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Mantle Cell Lymphoma, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Peripheral T-Cell Lymphomas (PTCL), Relapsed Multiple Myeloma, Waldenstrom Macroglobulinemia, Androgenic Alopecia, Arthritis, Auto Inflammatory Disease, B-Cell Chronic Lymphocytic Leukemia, Breast Cancer, Cancer Anorexia-Cachexia Syndrome, Chronic Asthma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Dermatomyositis, Eczema, Endometrial Cancer, Essential Thrombocythemia, Follicular Lymphoma, Gastric Cancer, Hairy Cell Leukemia, Hypopharyngeal Cancer, Inflammation, Inflammatory Bowel Disease, Laryngeal Cancer, Lupus Erythematosus, Lupus Nephritis, Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Prostate Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Myelofibrosis, Non-Hodgkin Lymphoma, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Plaque Psoriasis (Psoriasis Vulgaris), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Sicca Syndrome (Sjogren), Spondyloarthritis (Spondyloarthropathy), Systemic Lupus Erythematosus, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Thalassemia, Thrombocythemia Myelofibrosis, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Uveitis.

Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Overview
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Aclaris Therapeutics Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • CJ HealthCare Corp
  • Concert Pharmaceuticals Inc
  • Eli Lilly and Co
  • Galapagos NV
  • Han Wha Pharma Co Ltd
  • Incyte Corp
  • Japan Tobacco Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • LEO Pharma A/S
  • Nissan Chemical Industries Ltd
  • Pfizer Inc
  • Portola Pharmaceuticals Inc
  • Sareum Holdings Plc
  • Theravance Biopharma Inc
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drug Profiles
  • ABBV-599 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ATI-501 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ATI-502 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AZD-0449 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AZD-1480 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AZD-4205 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • baricitinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cerdulatinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CJ-15314 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CTP-543 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • delgocitinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • filgotinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INCB-52793 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • itacitinib adipate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LP-0184 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NIP-565 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • peficitinib hydrobromide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PF-04965842 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PF-06700841 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ruxolitinib phosphate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SAR-20347 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SART-29 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SHR-0302 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit JAK1 for Rheumatoid Arthritis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit JAK1 and JAK3 for Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Jak1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TD-1473 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • upadacitinib tartrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Dormant Products
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Discontinued Products
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Product Development Milestones
  • Featured News & Press Releases
  • Apr 25, 2018: Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
  • Apr 25, 2018: AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients
  • Apr 25, 2018: AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients
  • Apr 25, 2018: Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata
  • Apr 23, 2018: FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
  • Apr 23, 2018: Aclaris Therapeutics Announces First Patient Dosed in a Pilot Study with ATI-502 Topical in Patients with Androgenetic Alopecia
  • Apr 09, 2018: Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis
  • Feb 17, 2018: AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
  • Feb 16, 2018: AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn's Disease at 52 Weeks
  • Feb 14, 2018: Lilly to Showcase New Data for baricitinib at AAD Annual Meeting
  • Feb 14, 2018: Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
  • Feb 12, 2018: AbbVie to Present Data on Upadacitinib at 2018 American Academy of Dermatology Annual Meeting
  • Feb 12, 2018: Concert Pharmaceuticals Announces Initiation of Enrollment in Second Cohort of CTP-543 Phase 2a Trial for Alopecia Areata
  • Feb 08, 2018: Astellas Announce Top-Line Results for Two Phase 3 Trials of Peficitinib in Rheumatoid Arthritis Patients with Inadequate Response to Existing Therapy
  • Jan 12, 2018: Top-line Results of the Topical JTE-052 JAK Inhibitor Phase 3 Clinical Study (Comparative Study) in Japan
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..5), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..6), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..7), H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by AbbVie Inc, H1 2018
  • Pipeline by Aclaris Therapeutics Inc, H1 2018
  • Pipeline by Astellas Pharma Inc, H1 2018
  • Pipeline by AstraZeneca Plc, H1 2018
  • Pipeline by Bristol-Myers Squibb Co, H1 2018
  • Pipeline by CJ HealthCare Corp, H1 2018
  • Pipeline by Concert Pharmaceuticals Inc, H1 2018
  • Pipeline by Eli Lilly and Co, H1 2018
  • Pipeline by Galapagos NV, H1 2018
  • Pipeline by Han Wha Pharma Co Ltd, H1 2018
  • Pipeline by Incyte Corp, H1 2018
  • Pipeline by Japan Tobacco Inc, H1 2018
  • Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
  • Pipeline by LEO Pharma A/S, H1 2018
  • Pipeline by Nissan Chemical Industries Ltd, H1 2018
  • Pipeline by Pfizer Inc, H1 2018
  • Pipeline by Portola Pharmaceuticals Inc, H1 2018
  • Pipeline by Sareum Holdings Plc, H1 2018
  • Pipeline by Theravance Biopharma Inc, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018
  • Discontinued Products, H1 2018
  • Discontinued Products, H1 2018 (Contd..1), H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
Back to Top